![Arndt Vogel: FDA approves Melphalan as a liver-directed treatment for uveal melanoma.](https://oncodaily.com/pub/uploads/2023/08/Arndt-Vogel-1-e1691671535612-1280x799.jpeg)
Arndt Vogel: FDA approves Melphalan as a liver-directed treatment for uveal melanoma.
Arndt Vogel, Head of the GI-Cancer Center and of the Center for Personalized Medicine at Medical School Hannover, shared in a recent tweet:
“FDA approves melphalan as a liver-directed treatment for uveal melanoma.
Based on the FOCUS study: The overall Response Rate (ORR) is 36.3% and the median Duration of Response (mDoR) is 14 months.
We provide here a comprehensive review on chemosaturation in primary and secondary liver malignancies”
For the article click here.
Source: Arndt Vogel/Twitter
Arndt Vogel is a managing senior consultant and professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. He is the Head of the GI-Cancer Center and of the Center for Personalized Medicine at Medical School Hannover and chairs the Hepatobiliary Cancer Study Group of the AIO, a collaborative group in clinical oncology in Germany. His scientific focus is translational and clinical research in gastrointestinal cancer.